secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001297184-23-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q4 revenue $135M (+11.7% YoY); GAAP EPS $0.66; full-year revenue $499M (+14.0% YoY)
--------------------------------------------------------------------------------

- Q4 2022 net revenue $135.0M vs $120.9M YoY; GAAP net income $33.9M ($0.66 diluted EPS) vs $19.8M ($0.39).
- Full-year 2022 net revenue $499.0M vs $437.8M, GAAP net income $91.4M ($1.74) vs $62.1M ($1.25).
- Adjusted non-GAAP Q4 EPS $0.73, full-year $1.97; growth driven by epinephrine, Primatene MIST, and glucagon.
- CEO cites strongest quarter and anticipates multiple new product launches in 2023.
- No forward guidance provided; financial comparisons are to prior-year periods.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000012/0001297184-23-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718423000012/amph-20230228x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-23-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer